Price (delayed)
$26.03
Market cap
$6.64B
P/E Ratio
13.42
Dividend/share
N/A
EPS
$1.94
Enterprise value
$6.62B
Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are
There are no recent dividends present for MRVI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.